PDE5 inhibition against acute renal ischemia reperfusion injury in rats

Does vardenafil offer protection?

Iason Kyriazis, George C. Kagadis, Panagiotis Kallidonis, Ioannis Georgiopoulos, Antonia Marazioti, Aikaterini Geronasiou, Despina Liourdi, George Loudos, Vasilios Schinas, Dimitris Apostolopoulos, Helen Papadaki, Christodoulos Flordellis, George C. Nikiforidis, Andreas Papapetropoulos, Evangelos Liatsikos

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: To evaluate the effect of vardenafil on renal function after renal ischemia-reperfusion (IR) injury (IRI) in a rat model. Materials and methods: Seventy-one Wistar rats were divided into 7 groups including (1) a vehicle-treated group, (2) a vehicle pretreated-IR group, (3-6) vardenafil pretreated-IR groups in doses of 0.02, 0.2, 2 and 20 μg/kg, respectively, (7) a group of IR followed by treatment with 2 μg/kg of vardenafil. Vardenafil or vehicle solution was administered one hour before unilateral nephrectomy and the induction of 45 min of ischemia on the contralateral kidney by clamping of renal pedicle. Four hours of reperfusion were allowed after renal ischemia. Studied parameters were serum creatinine, fractional excretion of sodium (FENa), and histological evaluation of renal specimens. In addition, renal tissue cGMP levels, ERK1/2 phosphorylation as well as renal function by renal scintigraphy were also evaluated. Results: Administration of vardenafil before the induction of ischemia resulted in a significant reduction in creatinine and FENa levels as well as in less histological lesions observed in treated kidneys in comparison with the vehicle-treated group. The underlying mechanism of cytoprotection was cGMP depended and involved the phosphorylation of ERK proteins. Renal scintigraphy confirmed that PDE5 inhibition attenuates renal IRI. Conclusions: Vardenafil attenuates renal IRI. Based on similar results from relevant studies on other PDE-5 inhibitors in renal and cardiac IRI, it can be assumed that all PDE-5 inhibitors share a common mechanism of cytoprotection.

Original languageEnglish (US)
Pages (from-to)597-602
Number of pages6
JournalWorld Journal of Urology
Volume31
Issue number3
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Reperfusion Injury
Kidney
Ischemia
Reperfusion
Phosphodiesterase 5 Inhibitors
Cytoprotection
Vardenafil Dihydrochloride
Radionuclide Imaging
Creatinine
Wounds and Injuries
Phosphorylation
Nephrectomy
Constriction
Wistar Rats
Sodium

Keywords

  • Phosphodiesterase type 5 inhibitors
  • Renal ischemia
  • Reperfussion injury
  • Vardenafil

ASJC Scopus subject areas

  • Urology

Cite this

Kyriazis, I., Kagadis, G. C., Kallidonis, P., Georgiopoulos, I., Marazioti, A., Geronasiou, A., ... Liatsikos, E. (2013). PDE5 inhibition against acute renal ischemia reperfusion injury in rats: Does vardenafil offer protection? World Journal of Urology, 31(3), 597-602. https://doi.org/10.1007/s00345-012-0980-4

PDE5 inhibition against acute renal ischemia reperfusion injury in rats : Does vardenafil offer protection? / Kyriazis, Iason; Kagadis, George C.; Kallidonis, Panagiotis; Georgiopoulos, Ioannis; Marazioti, Antonia; Geronasiou, Aikaterini; Liourdi, Despina; Loudos, George; Schinas, Vasilios; Apostolopoulos, Dimitris; Papadaki, Helen; Flordellis, Christodoulos; Nikiforidis, George C.; Papapetropoulos, Andreas; Liatsikos, Evangelos.

In: World Journal of Urology, Vol. 31, No. 3, 01.06.2013, p. 597-602.

Research output: Contribution to journalArticle

Kyriazis, I, Kagadis, GC, Kallidonis, P, Georgiopoulos, I, Marazioti, A, Geronasiou, A, Liourdi, D, Loudos, G, Schinas, V, Apostolopoulos, D, Papadaki, H, Flordellis, C, Nikiforidis, GC, Papapetropoulos, A & Liatsikos, E 2013, 'PDE5 inhibition against acute renal ischemia reperfusion injury in rats: Does vardenafil offer protection?', World Journal of Urology, vol. 31, no. 3, pp. 597-602. https://doi.org/10.1007/s00345-012-0980-4
Kyriazis I, Kagadis GC, Kallidonis P, Georgiopoulos I, Marazioti A, Geronasiou A et al. PDE5 inhibition against acute renal ischemia reperfusion injury in rats: Does vardenafil offer protection? World Journal of Urology. 2013 Jun 1;31(3):597-602. https://doi.org/10.1007/s00345-012-0980-4
Kyriazis, Iason ; Kagadis, George C. ; Kallidonis, Panagiotis ; Georgiopoulos, Ioannis ; Marazioti, Antonia ; Geronasiou, Aikaterini ; Liourdi, Despina ; Loudos, George ; Schinas, Vasilios ; Apostolopoulos, Dimitris ; Papadaki, Helen ; Flordellis, Christodoulos ; Nikiforidis, George C. ; Papapetropoulos, Andreas ; Liatsikos, Evangelos. / PDE5 inhibition against acute renal ischemia reperfusion injury in rats : Does vardenafil offer protection?. In: World Journal of Urology. 2013 ; Vol. 31, No. 3. pp. 597-602.
@article{394cac81075842508492df9ed6d2f276,
title = "PDE5 inhibition against acute renal ischemia reperfusion injury in rats: Does vardenafil offer protection?",
abstract = "Purpose: To evaluate the effect of vardenafil on renal function after renal ischemia-reperfusion (IR) injury (IRI) in a rat model. Materials and methods: Seventy-one Wistar rats were divided into 7 groups including (1) a vehicle-treated group, (2) a vehicle pretreated-IR group, (3-6) vardenafil pretreated-IR groups in doses of 0.02, 0.2, 2 and 20 μg/kg, respectively, (7) a group of IR followed by treatment with 2 μg/kg of vardenafil. Vardenafil or vehicle solution was administered one hour before unilateral nephrectomy and the induction of 45 min of ischemia on the contralateral kidney by clamping of renal pedicle. Four hours of reperfusion were allowed after renal ischemia. Studied parameters were serum creatinine, fractional excretion of sodium (FENa), and histological evaluation of renal specimens. In addition, renal tissue cGMP levels, ERK1/2 phosphorylation as well as renal function by renal scintigraphy were also evaluated. Results: Administration of vardenafil before the induction of ischemia resulted in a significant reduction in creatinine and FENa levels as well as in less histological lesions observed in treated kidneys in comparison with the vehicle-treated group. The underlying mechanism of cytoprotection was cGMP depended and involved the phosphorylation of ERK proteins. Renal scintigraphy confirmed that PDE5 inhibition attenuates renal IRI. Conclusions: Vardenafil attenuates renal IRI. Based on similar results from relevant studies on other PDE-5 inhibitors in renal and cardiac IRI, it can be assumed that all PDE-5 inhibitors share a common mechanism of cytoprotection.",
keywords = "Phosphodiesterase type 5 inhibitors, Renal ischemia, Reperfussion injury, Vardenafil",
author = "Iason Kyriazis and Kagadis, {George C.} and Panagiotis Kallidonis and Ioannis Georgiopoulos and Antonia Marazioti and Aikaterini Geronasiou and Despina Liourdi and George Loudos and Vasilios Schinas and Dimitris Apostolopoulos and Helen Papadaki and Christodoulos Flordellis and Nikiforidis, {George C.} and Andreas Papapetropoulos and Evangelos Liatsikos",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/s00345-012-0980-4",
language = "English (US)",
volume = "31",
pages = "597--602",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - PDE5 inhibition against acute renal ischemia reperfusion injury in rats

T2 - Does vardenafil offer protection?

AU - Kyriazis, Iason

AU - Kagadis, George C.

AU - Kallidonis, Panagiotis

AU - Georgiopoulos, Ioannis

AU - Marazioti, Antonia

AU - Geronasiou, Aikaterini

AU - Liourdi, Despina

AU - Loudos, George

AU - Schinas, Vasilios

AU - Apostolopoulos, Dimitris

AU - Papadaki, Helen

AU - Flordellis, Christodoulos

AU - Nikiforidis, George C.

AU - Papapetropoulos, Andreas

AU - Liatsikos, Evangelos

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Purpose: To evaluate the effect of vardenafil on renal function after renal ischemia-reperfusion (IR) injury (IRI) in a rat model. Materials and methods: Seventy-one Wistar rats were divided into 7 groups including (1) a vehicle-treated group, (2) a vehicle pretreated-IR group, (3-6) vardenafil pretreated-IR groups in doses of 0.02, 0.2, 2 and 20 μg/kg, respectively, (7) a group of IR followed by treatment with 2 μg/kg of vardenafil. Vardenafil or vehicle solution was administered one hour before unilateral nephrectomy and the induction of 45 min of ischemia on the contralateral kidney by clamping of renal pedicle. Four hours of reperfusion were allowed after renal ischemia. Studied parameters were serum creatinine, fractional excretion of sodium (FENa), and histological evaluation of renal specimens. In addition, renal tissue cGMP levels, ERK1/2 phosphorylation as well as renal function by renal scintigraphy were also evaluated. Results: Administration of vardenafil before the induction of ischemia resulted in a significant reduction in creatinine and FENa levels as well as in less histological lesions observed in treated kidneys in comparison with the vehicle-treated group. The underlying mechanism of cytoprotection was cGMP depended and involved the phosphorylation of ERK proteins. Renal scintigraphy confirmed that PDE5 inhibition attenuates renal IRI. Conclusions: Vardenafil attenuates renal IRI. Based on similar results from relevant studies on other PDE-5 inhibitors in renal and cardiac IRI, it can be assumed that all PDE-5 inhibitors share a common mechanism of cytoprotection.

AB - Purpose: To evaluate the effect of vardenafil on renal function after renal ischemia-reperfusion (IR) injury (IRI) in a rat model. Materials and methods: Seventy-one Wistar rats were divided into 7 groups including (1) a vehicle-treated group, (2) a vehicle pretreated-IR group, (3-6) vardenafil pretreated-IR groups in doses of 0.02, 0.2, 2 and 20 μg/kg, respectively, (7) a group of IR followed by treatment with 2 μg/kg of vardenafil. Vardenafil or vehicle solution was administered one hour before unilateral nephrectomy and the induction of 45 min of ischemia on the contralateral kidney by clamping of renal pedicle. Four hours of reperfusion were allowed after renal ischemia. Studied parameters were serum creatinine, fractional excretion of sodium (FENa), and histological evaluation of renal specimens. In addition, renal tissue cGMP levels, ERK1/2 phosphorylation as well as renal function by renal scintigraphy were also evaluated. Results: Administration of vardenafil before the induction of ischemia resulted in a significant reduction in creatinine and FENa levels as well as in less histological lesions observed in treated kidneys in comparison with the vehicle-treated group. The underlying mechanism of cytoprotection was cGMP depended and involved the phosphorylation of ERK proteins. Renal scintigraphy confirmed that PDE5 inhibition attenuates renal IRI. Conclusions: Vardenafil attenuates renal IRI. Based on similar results from relevant studies on other PDE-5 inhibitors in renal and cardiac IRI, it can be assumed that all PDE-5 inhibitors share a common mechanism of cytoprotection.

KW - Phosphodiesterase type 5 inhibitors

KW - Renal ischemia

KW - Reperfussion injury

KW - Vardenafil

UR - http://www.scopus.com/inward/record.url?scp=84878243422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878243422&partnerID=8YFLogxK

U2 - 10.1007/s00345-012-0980-4

DO - 10.1007/s00345-012-0980-4

M3 - Article

VL - 31

SP - 597

EP - 602

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -